Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Vorland

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Genes|August 27, 2021
<i>HFE</i> Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary HemochromatosisMiriam Sandnes, Marta Vorland, Rune J Ulvik, et al.
Journal of Clinical Medicine|June 2, 2021
Hyperferritinemia-A Clinical OverviewMiriam Sandnes, Rune J Ulvik, Marta Vorland, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|December 8, 2022
Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasmsSusanne Lilleskare, Marta Vorland, Anh Khoi Vo, et al.
Bioscience Reports|July 3, 2013
Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyriaHelene J Bustad, Marta Vorland, Eva Rønneseth, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 9, 2016
Myeloproliferative neoplasms and JAK2 mutationsHenry Almedal, Marta Vorland, Aasne K Aarsand, et al.
Biochimica Et Biophysica Acta|June 5, 2003
Participation of phospholipase D and alpha/beta-protein kinase C in growth factor-induced signalling in C3H10T1/2 fibroblastsVidar A T Thorsen, Marta Vorland, Bodil Bjørndal, et al.
International Journal of Molecular Sciences|January 15, 2021
Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis RegulatorsHelene J Bustad, Juha P Kallio, Marta Vorland, et al.
Biomarker Research|November 28, 2018
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosisMarte Karen Brattås, Kyrre Lilleeng, Randi Hovland, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 8, 2019
A Pharmacological Chaperone Therapy for Acute Intermittent PorphyriaHelene J Bustad, Karen Toska, Caroline Schmitt, et al.
Annals of Hematology|December 12, 2018
International external quality assurance of JAK2 V617F quantificationJulia Asp, Vibe Skov, Beatriz Bellosillo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Genes|August 27, 2021
<i>HFE</i> Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary HemochromatosisMiriam Sandnes, Marta Vorland, Rune J Ulvik, et al.
Journal of Clinical Medicine|June 2, 2021
Hyperferritinemia-A Clinical OverviewMiriam Sandnes, Rune J Ulvik, Marta Vorland, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|December 8, 2022
Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasmsSusanne Lilleskare, Marta Vorland, Anh Khoi Vo, et al.
Bioscience Reports|July 3, 2013
Conformational stability and activity analysis of two hydroxymethylbilane synthase mutants, K132N and V215E, with different phenotypic association with acute intermittent porphyriaHelene J Bustad, Marta Vorland, Eva Rønneseth, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|December 9, 2016
Myeloproliferative neoplasms and JAK2 mutationsHenry Almedal, Marta Vorland, Aasne K Aarsand, et al.
Biochimica Et Biophysica Acta|June 5, 2003
Participation of phospholipase D and alpha/beta-protein kinase C in growth factor-induced signalling in C3H10T1/2 fibroblastsVidar A T Thorsen, Marta Vorland, Bodil Bjørndal, et al.
International Journal of Molecular Sciences|January 15, 2021
Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis RegulatorsHelene J Bustad, Juha P Kallio, Marta Vorland, et al.
Biomarker Research|November 28, 2018
Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosisMarte Karen Brattås, Kyrre Lilleeng, Randi Hovland, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 8, 2019
A Pharmacological Chaperone Therapy for Acute Intermittent PorphyriaHelene J Bustad, Karen Toska, Caroline Schmitt, et al.
Annals of Hematology|December 12, 2018
International external quality assurance of JAK2 V617F quantificationJulia Asp, Vibe Skov, Beatriz Bellosillo, et al.
Pageof 1